Date: 2018-02-20
Type of information: Establishment of a new subsidiary in the EU
Compound: Site-directed Enzyme Enhancement Therapy (SEE-Tx) platform
Company: Minoryx Therapeutics (Spain) Gain Therapeutics (Switzerland)
Therapeutic area: Technology - Services
Type agreement: establishment of a new subsidiary in the EU
Action mechanism:
- Pharmacological chaperones are a therapeutic approach with significant advantages over other treatments for rare metabolic diseases. This approach is based on using small molecules with a good pharmacokinetic profile to rescue mutated proteins whose loss of function is at the root of many rare diseases.
- The technology developed by Minoryx, now licensed to Gain Therapeutics, uses the three-dimensional structure of proteins originating from a patented computational technology initially discovered by the Barril Lab, University of Barcelona.
Disease:
Details:
- • On February 20, 2018, Minoryx Therapeutics and Gain Therapeutics announced the spin off of the Minoryx Site-directed Enzyme Enhancement Therapy (SEE-Tx) platform into Gain Therapeutics, a new company that will focus on using this platform to identify the next generation of non-competitive pharmacological chaperones.
- Gain Therapeutics, funded by private Swiss investors and by the TiVenture fund has its headquarters in Lugano (Switzerland), with a branch operating from Barcelona (Spain). The company has five discovery programs at various stages of development, all of which validate the platform and offer significant partnering opportunities. Researchers from the Minoryx laboratory at the Barcelona Science Park joined the new spin-off, under the scientific management of Dr Xavier Barril, ICREA researcher and co-founder of Minoryx Therapeutics, inventor of the technology.
- This new spin-off is part of Minoryx’s business strategy, in order to concentrate the company’s efforts on the clinical candidate MIN-102.
Financial terms:
Latest news:
Is general: Yes
